Guardian Pharmacy Services, Inc. (GRDN)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:06 AM ET
Guardian Pharmacy Services, Inc. (GRDN) Earnings: Report Dates and Results
Guardian Pharmacy Services (GRDN) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Guardian Pharmacy Services reported EPS of $0.30, above the $0.28 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GRDN has an expected report date of Mar 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.8% above the $0.37 reported for the quarter ended Dec 31, 2025.
GRDN Earnings Call
The latest GRDN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 9 quarters below that had an estimate, GRDN beat 6, missed 1 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $371.07M, down 1.7% from $377.43M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.30 | $0.28 | N/A | +7.14% | Beat | +20.0% | 7 | 4 up, 0 down | Nov 5, 2026 | $371.07M |
| Jun 30, 2026 | $0.24 | $0.24 | $0.24 - $0.28 | 0.00% | In line | +9.1% | 6 | 2 up, 2 down | Aug 6, 2026 | $351.77M |
| Mar 31, 2026 | $0.29 | $0.24 | $0.23 - $0.25 | +20.83% | Beat | +38.1% | 6 | 2 up, 2 down | May 6, 2026 | $336.60M |
| Dec 31, 2025 | $0.37 | $0.27 | $0.26 - $0.28 | +38.32% | Beat | +55.4% | 4 | 4 up, 0 down | Mar 11, 2026 | $397.62M |
| Sep 30, 2025 | $0.25 | $0.24 | $0.23 - $0.25 | +4.17% | Beat | -10.7% | 4 | 0 up, 1 down | Nov 10, 2025 | $377.43M |
| Jun 30, 2025 | $0.22 | $0.22 | N/A | 0.00% | In line | -10.2% | N/A | N/A | Aug 11, 2025 | $344.33M |
| Mar 31, 2025 | $0.21 | $0.22 | N/A | -4.55% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2025 | $329.31M |
| Dec 31, 2024 | $0.24 | $0.22 | N/A | +8.23% | Beat | N/A | 3 | 0 up, 0 down | Mar 26, 2025 | $338.57M |
| Sep 30, 2024 | $0.28 | $0.19 | N/A | +47.37% | Beat | N/A | N/A | N/A | Nov 12, 2024 | $314.39M |
| Jun 30, 2024 | $0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 22, 2024 | $300.04M |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | $0.83 | +56.6% |
| Jun 30, 2026 | $0.53 | -49.5% |
| Dec 31, 2025 | $1.05 | +145.9% |
| Jun 30, 2025 | $0.43 | -44.0% |
| Dec 31, 2024 | $0.76 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,789 | 11 | |
| 2026Q2 | Jun 30, 2026 | 3,942 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,071 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,153 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,918 | 7 |
2026Q3 Earnings Call
Opening remarks
Ashley Stockton Vice President, Investor Relations Good afternoon. Thank you for participating in today's conference call. This is Ashley Stockton, Vice President, Investor Relations for Guardian Pharmacy Services. I am joined on today's call by Fred Burke, President and Chief Executive Officer, David Morris, Chief Operating Officer, and Will Mudd, Chief Financial Officer. After market closed today, Guardian posted its financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's investor relations website. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release and quarterly report on Form 10-Q, as well as the specific risk factors and uncertainties discussed in our annual report on Form 10-K. We do not undertake any duty to update any forward-looking statements, which speak only as of the date they are made. On today's call, we will also use certain non-GAAP financial measures when discussing the company's financial performance and condition. You can find additional information on these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures in today's press release, which again is available on our investor relations website. Now, I will turn it over to Fred for high-level commentary.
Fred Burke President and Chief Executive Officer Thank you, Ashley, and good afternoon, everyone. We are extremely pleased with our performance this year and the momentum we are seeing across the business. Our results reflect the strength of the Guardian model, the dedication of our teams, and growing demand for high-quality pharmacy services in the long-term care setting. Given our performance year to date, we are raising our full-year guidance, which Will will discuss in more detail. Before I hand it over to David on operations, I would like to take a few minutes to discuss the broader economic environment, industry fundamentals, and how Guardian is positioned for continued growth. Looking across the broader economy, affordability, higher interest rates, and elevated operating costs all remain concerns. We believe the characteristics of the markets we serve and our business model help insulate Guardian from many of these issues. First, on affordability, it's well-documented that those 75 and over are among the wealthiest segment of the population. We believe this provides an important foundation for long-term demand for private pay assisted living, which represents approximately 70% of the residents we serve.
Frequently Asked Questions About GRDN
When is Guardian Pharmacy Services's next earnings date?
Guardian Pharmacy Services's next earnings report is expected for Mar 9, 2027.
Did GRDN beat earnings estimates last quarter?
Yes. Guardian Pharmacy Services reported EPS of $0.30 for the quarter ended Sep 30, 2026, above the $0.28 estimate, a 7.14% surprise.
What EPS do analysts expect from GRDN next quarter?
The consensus EPS estimate for Guardian Pharmacy Services for the quarter ending Dec 31, 2026 is $0.41 from 9 analysts, with estimates from $0.36 to $0.47.
How often does GRDN beat earnings estimates?
Guardian Pharmacy Services beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +9.27%.
GRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors